Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela Hartigan

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Epidemiologic Reviews|July 18, 2002
Analysis of randomized controlled trialsPeter Peduzzi, William Henderson, Pamela Hartigan, et al.
Plos One|January 27, 2017
Supporting Better Evidence Generation and Use within Social Innovation in Health in Low- and Middle-Income Countries: A Qualitative StudyMadeleine Ballard, Jenny Tran, Fred Hersch, et al.
Heart & Lung : the Journal of Critical Care|September 12, 2006
The synergistic effect of heart disease and diabetes on self-management, symptoms, and health statusChristi Deaton, Laura P Kimble, Emir Veledar, et al.
JAMA|September 13, 2007
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trialRex L Jamison, Pamela Hartigan, James S Kaufman, et al.
JAMA Internal Medicine|December 4, 2013
Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trialsKathleen Stergiopoulos, William E Boden, Pamela Hartigan, et al.
Clinical Trials (London, England)|November 11, 2005
Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) studyRex L Jamison, Pamela Hartigan, J Michael Gaziano, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 25, 2009
Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine studyChristopher B Brady, J Michael Gaziano, Roberta A Cxypoliski, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2018
Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)Zugui Zhang, Philip Jones, William S Weintraub, et al.
Journal of the American College of Cardiology|March 19, 2013
Risk factor control for coronary artery disease secondary prevention in large randomized trialsMichael E Farkouh, William E Boden, Vera Bittner, et al.
Journal of the American College of Cardiology|February 2, 2019
Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With DiabetesMichael E Farkouh, Mandeep S Sidhu, Maria M Brooks, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Epidemiologic Reviews|July 18, 2002
Analysis of randomized controlled trialsPeter Peduzzi, William Henderson, Pamela Hartigan, et al.
Plos One|January 27, 2017
Supporting Better Evidence Generation and Use within Social Innovation in Health in Low- and Middle-Income Countries: A Qualitative StudyMadeleine Ballard, Jenny Tran, Fred Hersch, et al.
Heart & Lung : the Journal of Critical Care|September 12, 2006
The synergistic effect of heart disease and diabetes on self-management, symptoms, and health statusChristi Deaton, Laura P Kimble, Emir Veledar, et al.
JAMA|September 13, 2007
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trialRex L Jamison, Pamela Hartigan, James S Kaufman, et al.
JAMA Internal Medicine|December 4, 2013
Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trialsKathleen Stergiopoulos, William E Boden, Pamela Hartigan, et al.
Clinical Trials (London, England)|November 11, 2005
Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) studyRex L Jamison, Pamela Hartigan, J Michael Gaziano, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 25, 2009
Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine studyChristopher B Brady, J Michael Gaziano, Roberta A Cxypoliski, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2018
Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)Zugui Zhang, Philip Jones, William S Weintraub, et al.
Journal of the American College of Cardiology|March 19, 2013
Risk factor control for coronary artery disease secondary prevention in large randomized trialsMichael E Farkouh, William E Boden, Vera Bittner, et al.
Journal of the American College of Cardiology|February 2, 2019
Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With DiabetesMichael E Farkouh, Mandeep S Sidhu, Maria M Brooks, et al.
Pageof 2